Cargando…

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

Monthly doses of palivizumab, an RSV-specific monoclonal antibody, reduce RSV-related hospitalizations (RSVH) in high-risk children; however, no specific palivizumab level has been correlated with disease severity in humans. A post hoc analysis of a previous randomized, placebo-controlled trial eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forbes, Michael L, Kumar, Veena R, Yogev, Ram, Wu, Xionghua, Robbie, Gabriel J, Ambrose, Christopher S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443068/ https://www.ncbi.nlm.nih.gov/pubmed/25483663 http://dx.doi.org/10.4161/hv.29635

Ejemplares similares

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Human respiratory syncytial virus and other viral infections in infants receiving palivizumab
por: Boivin, Guy, et al.
Publicado: (2008)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections
por: Ambrose, Christopher S.
Publicado: (2017)

Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
por: Matías, Israel, et al.
Publicado: (2014)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age
por: Franklin, Jeremy A., et al.
Publicado: (2016)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
por: Viguria, Natividad, et al.
Publicado: (2021)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit
por: Alan, S., et al.
Publicado: (2012)

Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
por: Edirisinghe, Hasindu S., et al.
Publicado: (2023)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Respiratory Syncytial Virus Pneumonia Treated with Lower-Dose Palivizumab in a Heart Transplant Recipient
por: Grodin, J. L., et al.
Publicado: (2012)

Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon
por: Abou-El-Hassan, Hadi, et al.
Publicado: (2019)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
por: Antepowicz, Agata, et al.
Publicado: (2021)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Residential crowding and severe respiratory syncytial virus disease among infants and young children: A systematic literature review
por: Colosia, Ann D, et al.
Publicado: (2012)

Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis
por: Anderson, Evan J., et al.
Publicado: (2017)

Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia
por: Han, Young Mi, et al.
Publicado: (2015)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
por: Elhalik, M., et al.
Publicado: (2019)

Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection
por: Mori, Masaaki, et al.
Publicado: (2021)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2qs53v8poh6bi7097j60fpuf8c